Coastal Infusion Administers Tzield™

Tzield (teplizumab-mzwv) is used to delay the onset of Stage 3 type 1 diabetes in patients who have Stage 2 type 1 diabetes. This means that they have tested positive for 2 or more type 1 diabetes-related autoantibodies, have abnormal blood sugar levels, and do not have type 2 diabetes.

The active substance in Tzield, teplizumab, targets CD3, a protein found on the surface of T cells. By binding to CD3, teplizumab aims to modulate the T cell response, potentially reducing the immune system’s attack on the insulin-producing cells. This modulation is intended to slow down or prevent the progression of type 1 diabetes.

What It Treats

Tzield is used to delay the onset of Stage 3 Type 1 diabeties.

Prescribed By

• Endocrinologists
• Diabetologists

How it’s Administered

Tzield is administered by intravenous infusion. Tzield injections take about 30 minutes.

Frequency

Tzield is generally administered every day for 14 days.

Additional Resources

• Tzield Website
• Prescribing Information
• Co-Pay Assistance

The information on this page is compiled from a variety of online sources. Coastal Infusion has made every effort to verify its accuracy, but patients are advised to discuss any planned or current treatments with their doctor. Report inaccuracies